Attorneys representing the state of Louisiana and 340B providers urged a federal judge to dismiss AstraZeneca’s lawsuit against Louisiana’s contract [...] …
Year: 2023
Critics of the 340B program, including a former congressman who voted to create the program, have written recent editorials urging [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The 340B drug pricing program allows covered entities serving vulnerable patient populations to buy medications at a discount. Since 1987, AIDS Healthcare Foundation has been on the frontline of the HIV response in the United States. AHF cares for patients regardless of their ability to pay. For AHF, 340B savings offset the costs of the critical services it provides to people living with HIV.
The 340B program transforms the healthcare landscape by leveling the playing field so providers can more effectively serve vulnerable communities. When individuals have access to affordable healthcare, they are more likely to seek necessary treatment and preventive services.
We will explore some key aspects of the 340B program with AHF Assistant Director of Prevention Jomil Luna. As a steadfast supporter of the 340B program, Jomil is a passionate public health and LGBTQ advocate in the New York community. He received his Master’s in Public Health from Rutgers University,
…
When I thought about launching 340B Report, the first person I reached out to was Tom Mirga. Tom and I [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Veteran 340B observers were surprised to see that Sen. Bill Cassidy (R-La.) has expanded his 340B investigation into community health [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal regulators have approved a first-time 340B provider audit by a drug manufacturer to examine processes to prevent duplicate discounts [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal regulators recently deferred a decision on whether to add identifiers to 340B drugs purchased under Medicare Part D. The [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
After 30 years of serving vulnerable populations, the 340B Drug Pricing Program has grown considerably in scale and complexity. While it is arguably one of the most successful public/private partnerships in healthcare history, 340B is facing policy obstacles and headwinds that can make administering a program more challenging for covered entities than ever. This includes manufacturers limiting discounts to a single contract pharmacy and excluding high-cost drugs from the program. 340B administration is also complicated by perennial regulatory updates from CMS that impact the program directly and indirectly.
For these reasons and more, it can often make sense for covered entities to seek the expertise and assistance of a 340B vendor to reduce the complexity and optimize the savings from 340B. When you are working with partners, it’s important to ensure you are setting yourself up for success and the greatest return on your investment from the start. The implementation and onboarding process
…
Who will succeed retiring Rep. Anna Eshoo (D-Calif.) as top Democrat on the House Energy & Commerce (E&C) subcommittee that [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Japanese pharmaceutical giant Takeda last Friday became the 29th drugmaker to place conditions on 340B pricing in the contract pharmacy [...] …